Ocuphire Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops

Ocuphire Pharma has entered into an exclusive license agreement with FamyGen Life Sciences for the development and commercialization of Nyxol across three indications in US, Europe, Japan, India, China, and other global markets.

Ocuphire Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops
November 08, 2022
More